Merck & Company, Inc. Press Releases

MRK 
$59.8001
*  
0.4201
0.71%
Get MRK Alerts
*Delayed - data as of Nov. 21, 2014 11:12 ET  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
11/17/2014 11:45:00 AM - PR Newswire


VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
11/17/2014 11:45:00 AM - Business Wire


Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
11/17/2014 8:30:00 AM - Business Wire


Merck KGaA, Darmstadt, Germany, Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
11/17/2014 3:40:00 AM - Business Wire


MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
11/16/2014 4:25:00 AM - Business Wire


Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
11/16/2014 4:25:00 AM - Business Wire


Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
11/11/2014 8:00:00 AM - Business Wire


Ruy Halffter Joins Evercore Casa de Bolsa as Head of the Equity Capital Markets Group
11/11/2014 8:00:00 AM - Business Wire


Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®
11/9/2014 6:53:00 PM - Business Wire
▲0.78 % Price Change since this news event. The Volume Ratio is 1.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
11/7/2014 11:00:00 AM - PR Newswire
▲0.88 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
11/6/2014 9:08:00 AM - Business Wire
▲0.00 % Price Change since this news event. The Volume Ratio is 0.99.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
11/5/2014 8:30:00 AM - Business Wire
▲0.96 % Price Change since this news event. The Volume Ratio is 1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
11/3/2014 5:00:00 AM - Business Wire
▲3.28 % Price Change since this news event. The Volume Ratio is 0.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Third-Quarter 2014 Financial Results
10/27/2014 7:00:00 AM - Business Wire
▲3.80 % Price Change since this news event. The Volume Ratio is 1.24.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
10/27/2014 6:45:00 AM - Business Wire
▲3.10 % Price Change since this news event. The Volume Ratio is 1.24.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


GNS Healthcare Expands Executive Team with Addition of Three Industry Veterans
10/20/2014 8:55:00 AM - Business Wire


Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
10/20/2014 8:00:00 AM - PR Newswire
▲10.64 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
10/20/2014 8:00:00 AM - Business Wire
▲10.64 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Final Results of Tender Offers for Eight Series of Notes
10/15/2014 8:00:00 AM - Business Wire
▲6.46 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Pricing of Tender Offers for Eight Series of Notes
10/14/2014 6:20:00 PM - Business Wire
▲6.16 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
10/8/2014 11:13:00 AM - Business Wire


Merck Prices EUR 2.5 Billion Debt Offering
10/6/2014 12:28:00 PM - Business Wire


Merck Announces Proposed Public Debt Offering
10/6/2014 3:24:00 AM - Business Wire


Merck Announces Tender Offers for Eight Series of Notes
10/6/2014 3:18:00 AM - Business Wire


Merck Congratulates Ecuador as Second Country to Receive PAHO/WHO Verification of Elimination of River Blindness
10/3/2014 9:00:00 AM - Business Wire